Summary
Background
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Golimumab making it ideal for research use. This Golimumab biosimilar reacts with human TNFα (tumor necrosis factor-alpha) a multifunctional proinflammatory cytokine. TNFα exists as a soluble 17 kDa monomer, which forms homotrimers in circulation or as a 26 kDa membrane-bound form. TNFα belongs to the TNF superfamily of cytokines and signals through its two receptors, TNFR1 and TNFR2 which can be activated by both the soluble trimeric and membrane-bound and forms of TNFα. TNFα is primarily produced by macrophages in response to foreign antigens such as bacteria (lipopolysaccharides), viruses, and parasites as well as mitogens and other cytokines but can also be expressed by monocytes, neutrophils, NK cells, CD4 T cells and some specialized dendritic cells. TNFα is known to play key roles in a wide spectrum of biological processes including immunoregulation, cell proliferation, differentiation, apoptosis, antitumor activity, inflammation, anorexia, cachexia, septic shock, hematopoiesis, and viral replication. TNFα dysregulation has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Golimumab binds to both the soluble and transmembrane forms of human TNF-α, neutralizing its biological activity and preventing downstream signaling through TNF receptors. Therapeutically, Golimumab is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, where it helps reduce inflammation and tissue damage by blocking TNF-α–mediated pathways. This biosimilar antibody is ideal for investigating TNF-α biology, modeling anti-TNF therapies, and exploring cytokine signaling in inflammatory diseases.
